Streetbeat News

TRHC

Tabula Rasa HealthCare Inc

http://www.tabularasahealthcare.com/

CEO

Calvin Knowlton

Employees

585

Industry

Tobacco Manufacturing

the tabula rasa healthcare family of companies provide new beginnings for our clients, through innovative service models and fresh approaches to healthcare technology. our leaders understand that to maximize patient experiences and outcomes, they must help providers to balance efficiency and scalability with safety and individualization of care.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

US stocks traded higher with the Dow Jones gaining more than 350 points. Henry Schein Inc reported better-than-expected Q2 earnings but slightly missed sales consensus. Vistagen Therapeutics, Tabula Rasa HealthCare, and Sequans Communications saw their shares rise after positive news. Sage Therapeutics, Tivic Health Systems, and Yellow Corporation saw their shares drop due to negative developments.

Portfolio Pulse from Lisa Levin

August 07, 2023 | 6:30 pm

Nautic Partners has agreed to acquire Tabula Rasa HealthCare Inc (NASDAQ:TRHC) for $10.50 per share in cash, valuing the company at approximately $570 million. The deal will combine Tabula Rasa with ExactCare Pharmacy, another Nautic portfolio company. The transaction is expected to close in Q4 2023. Tabula Rasa's Q2 adjusted EPS was $0.03, beating the consensus of $(0.14), and sales were $90.04 million, beating the consensus of $88.82 million. William Blair analysts have downgraded the stock to Market Perform from Outperform.

Portfolio Pulse from Vandana Singh

August 07, 2023 | 5:34 pm

During Monday's intraday session, several healthcare stocks experienced significant movements. Vistagen Therapeutics, Nektar Therapeutics, Tabula Rasa HealthCare, Poseida Therapeutics, Enveric Biosciences, and Palatin Techs saw their shares rise, with Vistagen Therapeutics leading the gainers with an 871.4% increase. On the other hand, Sage Therapeutics, Tivic Health Systems, Aceragen, Quantum-Si, Infinity Pharmaceuticals, and BIMI Intl Medical saw their shares fall, with Sage Therapeutics leading the losers with a 52.3% decrease.

Portfolio Pulse from Benzinga Insights

August 07, 2023 | 5:31 pm

The article lists the stocks that gained and lost the most during Monday's mid-day trading session. Among the gainers were Vistagen Therapeutics, Save Foods, Poseida Therapeutics, and Missfresh Limited, all of which saw significant jumps in their share prices due to various positive developments. On the other hand, Sage Therapeutics, Tivic Health Systems, Yellow Corporation, and Quantum-Si incorporated were among the biggest losers, with their shares tumbling due to negative news such as worse-than-expected results and regulatory setbacks.

Portfolio Pulse from Lisa Levin

August 07, 2023 | 5:28 pm

William Blair analyst Ryan Daniels has downgraded Tabula Rasa HealthCare (NASDAQ:TRHC) from Outperform to Market Perform.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 4:33 pm

U.S. stocks were higher with the Dow Jones gaining over 300 points. Henry Schein Inc reported better-than-expected Q2 earnings with sales of $3.10 billion, slightly missing the consensus of $3.11 billion. Vistagen Therapeutics, Tabula Rasa HealthCare, and Sequans Communications saw their shares rise after positive news. Sage Therapeutics, Tivic Health Systems, and Yellow Corporation saw their shares drop due to negative developments.

Portfolio Pulse from Lisa Levin

August 07, 2023 | 4:01 pm

Tabula Rasa HealthCare's shares are trading higher following the company's Q2 financial results, which exceeded expectations.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 1:10 pm

Several healthcare stocks experienced significant movement in Monday's pre-market session. Vistagen Therapeutics, Nektar Therapeutics, Tabula Rasa HealthCare, T2 Biosystems, Gracell Biotechnologies, and Protalix BioTherapeutics saw increases, while Sage Therapeutics, Tivic Health Systems, Aceragen, Quantum-Si, Apellis Pharmaceuticals, and HUTCHMED (China) saw declines. Q2 earnings were released for several of these companies.

Portfolio Pulse from Benzinga Insights

August 07, 2023 | 1:05 pm

Tabula Rasa HealthCare (NASDAQ:TRHC) reported Q2 earnings of $0.03 per share, beating the analyst consensus estimate of $(0.14) by 121.43%. This is a 105.66% increase from the same period last year. The company also reported quarterly sales of $90.04 million, beating the analyst consensus estimate of $88.82 million by 1.37%, a 24.02% increase from the same period last year.

Portfolio Pulse from Happy Mohamed

August 07, 2023 | 12:10 pm

Tabula Rasa HealthCare (NASDAQ:TRHC) reported Q2 losses of $(0.38) per share, missing the analyst consensus estimate of $(0.14) by 171.43%. However, the company reported quarterly sales of $90.04 million, beating the estimate of $88.82 million by 1.37%. This represents a 24.02% increase over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 11:14 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.